Note №29REGULATORY RECORD
You had HIFU lifting in Seoul. Back home, you tell your dermatologist you had “Shurink.” They have never heard of it — and neither has any regulator in their country. That is not because the machine is obscure. It is because in Korean clinics, several of the most common device and product names change — or quietly stop existing — the moment you cross a border.
We have verified each example below against primary regulatory records for earlier articles on this site; this piece collects them in one place, because the pattern itself is the useful knowledge.
Same machine, different passport
| Name on the Korean menu | What it is elsewhere |
|---|---|
| 슈링크 (Shurink) | Sold abroad as Ultraformer. No FDA clearance exists under either name; the manufacturer’s US-cleared devices are different models entirely |
| 울쎄라 (Ulthera) | Real US device — but authorised via a De Novo pathway (2009) and later 510(k)s, which is not the same thing as “FDA approved” |
| 써마지 (Thermage) | US 510(k)-cleared — with cleared indications that do not include the lifting language Korean marketing uses |
| 리쥬란 (Rejuran) | Long called “Asia-only” — no longer true: it obtained EU CE marking under the MDR in December 2024. It remains unavailable in the US |
| 스컬트라 (Sculptra) | The rare one with a full FDA premarket approval (PMA) |
Why this matters more than trivia
- Your aftercare depends on it. A doctor at home cannot look up “Shurink.” Ask your Korean clinic to write down the device’s export name and the treatment parameters — and keep it with your treatment records.
- “FDA approved” usually is not. Most aesthetic devices reach the US market through clearance pathways (510(k), De Novo) that involve far less evidence than approval. When a clinic’s English page says “FDA approved,” the accurate word is usually “cleared” — and sometimes neither applies to the Korean-market model at all.
- Names are marketing territory. Korean treatment menus already run on nickname conventions; device branding by market is one more layer. None of this means the treatment is bad — it means the name alone is not information.
What this article does not claim
Nothing here says these devices are unsafe or ineffective, and no clinic is named. Regulatory status describes what a regulator has reviewed — not how good the treatment is. Statuses also change; the entries above reflect records as verified for our earlier coverage and re-checked on the date below.
Sources and last verification
- FDA device databases (De Novo DEN080006 for Ultherapy; 510(k) K170758 for Thermage FLX; PMA P030050/S039 for Sculptra) — verified for earlier articles on this site — re-checked 18 August 2026
- EU CE MDR certification of Rejuran (26 December 2024) — manufacturer announcement, previously verified — accessed 18 August 2026
- Classys (Shurink/Ultraformer manufacturer) US clearance records — previously verified: no clearance under the Shurink or Ultraformer names — accessed 18 August 2026
A name is only the first layer. The regulatory sentence attached to a device can be narrower still: we read the clearance text for four Korean radiofrequency devices and not one of them mentions a wrinkle.
Verified 18 August 2026. Regulatory statuses change; check the FDA and EU databases for the current record.
Related. One layer below the name is the packaging. Korean law fixes what must be printed on a device box and on a drug vial — and two of those items can be checked against a public database before treatment: what to read on the box, and what opening it does not prove.
Leave a Reply